Table 2.
Pathways perturbed by lovastatin treatment, as identified by IPA.
Ingenuity Canonical Pathways | Proteins |
---|---|
Estrogen Receptor Signaling | TAF9, SRA, general transcription factor TFIIB, MED1, MED12 |
Glutamate Metabolism | GS, γ-ECS |
Protein Ubiquitination Pathway | BIRC6, USP10, DNAJC2, UBE2S, UBE2J1, HLA-C |
Cholesterol Biosynthesis | HMGCS, FDFT1 |
EIF2 Signaling | EIF3G, EIF4G1, EIF2A |